Tibra Equities Europe’s VYNE Therapeutics VYNE Stock Holding History

Tibra Equities Europe’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-5,056	Closed	-$319K	–	191
2021 Q2	$319K	Buy	+5,056	New	+$400K	0.1%	150

Other funds holding VYNE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tibra Equities Europe's VYNE Position: Q3 2021 in Review

Tibra Equities Europe sold out of VYNE Therapeutics (VYNE) in Q3 2021, closing a stake of 5,056 shares — an estimated $319K sold.

Tibra Equities Europe first reported a position in VYNE in Q2 2021 and held it in 1 quarter. The position peaked at $319K in Q2 2021. 64 funds tracked by Wall St. Rank hold VYNE as of Q3 2021.

Tibra Equities Europe reported no remaining VYNE Therapeutics position as of Q3 2021 after selling out during the quarter.
Tibra Equities Europe sold 5,056 VYNE Therapeutics shares in Q3 2021, an estimated $319K.
Tibra Equities Europe first reported a position in VYNE Therapeutics in Q2 2021 and held it in 1 quarter.
Tibra Equities Europe's VYNE Therapeutics position peaked at $319K in Q2 2021.
64 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q3 2021.

Based on Tibra Equities Europe's 13F filing for Q3 2021, filed 15 Nov 2021.